England’s health technology assessment (HTA) body NICE has recommended Eli Lilly and Company’s Mounjaro (tirzepatide) for National Health Service use to treat patients with poorly controlled type 2 diabetes in 8 September draft guidance.
The positive reimbursement decision from NICE, which could see Mounjaro offered to up to 180,000 patients, reversed the HTA body’s...







